Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 518 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Rash Clear all
Completed Phase 3 Interventional Results available

A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

NCT03028363
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Olumacostat Glasaretil Gel, 5.0%, Olumacostat Glasaretil Gel, Vehicle
Drug · Other
Lead sponsor
Dermira, Inc.
Industry
Eligibility
9 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
38
States / cities
Phoenix, Arizona • Anaheim, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 31, 2026, 3:39 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

NCT01256489
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Corneal Blindness
Interventions
Infliximab
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 31, 2026, 3:39 AM EDT
Completed No phase listed Observational

Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment

NCT01727440
View directory record Official record
Conditions
Acne Vulgaris, Isotretinoin
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
12 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
6
States / cities
Concord, North Carolina • Davidson, North Carolina • Harrisburg, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 3 Interventional Results available

Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

NCT03915860
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
9
States / cities
Fort Smith, Arkansas • Beverly, Massachusetts • Portsmouth, New Hampshire + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 3 Interventional Results available

Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance

NCT00687908
View directory record Official record
Conditions
Acne
Interventions
Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel, Vehicle Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
San Diego, California • Denver, Colorado • Longmont, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne

NCT06415305
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Winlevi (clascoterone) 1% cream
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris

NCT06063473
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream 0.005%, Placebo, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
762 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo

NCT01135069
View directory record Official record
Conditions
Acne
Interventions
Tretinoin microsphere 0.1%, Brand Retin-A Micro tretinoin microsphere gel 0.1%, placebo microsphere gel
Drug
Lead sponsor
Spear Pharmaceuticals
Industry
Eligibility
12 Years to 40 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Land O' Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

NCT00651469
View directory record Official record
Conditions
Acne Vulgaris
Interventions
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 31, 2026, 3:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Analysis of Lyme Disease Lesions

NCT00132327
View directory record Official record
Conditions
Erythema Migrans Lesions, Erythema Migrans
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 3 Interventional Results available

CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris

NCT02189629
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 (trifarotene)
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Mobile, Alabama • Rogers, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 1 Interventional

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

NCT04134273
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CLPG Topical Gel 1%, Clindamycin, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers

NCT01830764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Red Light (PDT)
Drug
Lead sponsor
Dermira, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Safety and Tolerability of a Brightening Treatment Paired With a Skincare Regimen

NCT07501000
View directory record Official record
Conditions
Hyperpigmentation, Skin Ageing, Post Inflammatory Hyperpigmentation, Skin Roughness
Interventions
Brightening Treatment
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
20 Years to 65 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris

NCT04883736
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Gel Microsphere, 0.1%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
973 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 4 Interventional Results available

Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications

NCT00926367
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin and benzoyl peroxide, benzoyl peroxide 2.5% and adapalene 0.1% gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Early Phase 1 Interventional

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

NCT03471364
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Ketoconazole, Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Danville, Illinois • Urbana, Illinois • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 3:39 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

NCT03115567
View directory record Official record
Conditions
Acneiform Rash, Papulopustular Eruption
Interventions
Triamcinolone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 31, 2026, 3:39 AM EDT
Completed No phase listed Observational

Etiology of Eczema Herpeticum (EH)

NCT03038932
View directory record Official record
Conditions
Eczema Herpeticum
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 64 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 3 Interventional Results available

Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction

NCT01559922
View directory record Official record
Conditions
Atrophic Acne Scar
Interventions
Normal Saline, Artefill
Drug · Device
Lead sponsor
Suneva Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Beverly Hills, California • Los Angeles, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

NCT03717506
View directory record Official record
Conditions
Acne Vulgaris
Interventions
GDC 268 Lotion, Clindamycin Phosphate Lotion 1%, GDC Vehicle Lotion
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
34
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 2 Interventional Results available

Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients

NCT01160848
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Area cleaned with saline water and occluded with Tegaderm, Area cleaned with saline water, Area cleaned with Ethyl alcohol solution, Visonac left on the skin for 24 hours in facial area one, Visonac wiped off after one hour, Visonac left on the skin 24 hours in facial area two
Drug
Lead sponsor
Photocure
Industry
Eligibility
12 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 31, 2026, 3:39 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus

NCT01041625
View directory record Official record
Conditions
Lichen Planus
Interventions
Apremilast (CC-10004)
Drug
Lead sponsor
Virginia Clinical Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 1, 2010 · Synced Oct 31, 2026, 3:39 AM EDT
Completed Phase 2 Interventional Results available

Topical Ruxolitinib Lichen Planus

NCT03697460
View directory record Official record
Conditions
Lichen Planus
Interventions
INCB018424
Drug
Lead sponsor
Aaron R. Mangold
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 31, 2026, 3:39 AM EDT